
December 30, 2024 to January 3, 2025 4:00 PM
For this week an initial hypothetical investment of $10,000 yielded $137,009 (that's right … $137,009 (4-trading days) in net gains from the companies of our memorable trades. Naturally, the fully documented results as stated may not represent future transactions, but if history is the judge, our G-101-SPM AI algorithm for this week has hooked a WHALE.
MISSION STATEMENT: To prove that non-human intervention by an analytical dotbot is far superior to the other kind.
Note: On January 2, 2025 we began Beta testing eight new data fields as a means to anticipate and react to the evolving dynamics of political realities and related trading anomalies. The intention is to enhanced the subsets from 129 to 137 by operating two separate systems until the new data stream is fully integrated. Any modification, if necessary, to the generative subsets will be introduced to the platform and become effective March 1, 2025. Once complete and fully operational, we plan to commence a new service called G-101 SPM AI Email Platform Component – EPC for all FLASHTRADES, short term and midterm term trading ideas, and immediately transmit the data to private email addresses of our subscribers, and repost the data the following day to our Stocktwists landing pages. As requested by certain followers, the EPC component should enhance the speed of data notification without affecting the majority of our followers who use the Stocktwists landing pages for long term investment ideas and daily abstracts: SPMNOTES FIRSTLOOK OPTIONACTION INSIDERS DILUTION SHOWTIME NOISE QUESTIONBOX SURVEYS .
Service costs and procedures for G-101 SPM AI Email Platform Component – EPC will be posted at a later date.
PART ONE
1.3.25
OPTIONACTION
$OKLO $26.63 +4.78 bid. SELL CALL OPTIONS/TAKE PROFIT
OKLO January 17, 2025 $20.00 CALL current value $6.90 bid.
* DAC (dollar average cost) $2.50 (12.31.24)
* note: RETAIN LONG POSITION
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
note: The $OKLO pick was responsible for 18% of this week’s gain.
1.3.25
$CRNC $17.74 +9.72 bid. SELL/TAKE PROFIT on 20%.
*DAC (dollar average cost incudes partial gain to reduce cost to $0.72.)
CHANGE EXIT TO $25.00 FROM $12.00.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
note: The $CRNC pick was responsible for 34% of this week’s gain.
1.3.25
$ETON $14.90 bid. DAC (dollar average cost) $4.01 (4.11.23).
EXIT $25.00 Legacy Holding status.
BRIEF: Advances its commitment to rare disease with the acquisition of Galzin (zinc acetate).
note: Galzin is FDA-approved as a maintenance treatment of patients with Wilson Disease who have been initially treated with a chelating agent. It is estimated that less than 5,000 patients in the United States are currently being treated for Wilson Disease.
Eton expects to assume the commercialization of the product in the United States in the first quarter of 2025 with its metabolic sales force supporting healthcare professionals who treat Wilson Disease. Once available, Eton plans to offer the product through its Eton Cares patient support program that provides high-touch, personalized service tailored for rare disease patients and their providers.
1.3.25
$QSI $4.53 bid. SELL/TAKE PROFIT on 30% of net position.
* DAC (dollar average cost includes this partial liquidation to reduce cost to zero) $00.00 / initial position was at $1.38 (11.20.24).
CHANGE EXIT TO $8.00 FROM $6.50.
OVRERVIEW: Quantum-Si is a life sciences company focused on developing a single-molecule detection platform for Next Generation Protein Sequencing. The company has expanded its international distribution network to 15 partners and introduced innovative tools like the Platinum Library Prep Kit V2 and the protein Barcoding Kit, enhancing proteomics research capabilities.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
1.2.25
OPTIONACTION
$LYFT $13.54 +0.65 bid. DAC (dollar average cost) $11.27 (5.3.24). EXIT $26.00 (long term).
BRIEF: Lyft call volume above normal and directionally bullish
Bullish option flow detected in Lyft(LYFT) with 48,344 calls trading, 5x expected, and implied vol increasing over 2 points to 52.07%. 1/3 weekly 14 calls and 1/10 weekly 14 calls are the most active options, with total volume in those strikes near 23,200 contracts.
note: The Put/Call Ratio is 0.17.
note: Earnings are expected on February 13th.
1.2.25
FLASHTRADE
$ALCE $2.25 bid. SELL/TAKE PROFIT. DAC (dollar average cost)$1.36 (1.2.25).
PLAN TO REVISIT.
1.2.25 $ALCE $1.36 ask. BUY/NEW LONG POSITION carries SPM 82.45 tag RISK to $2.25 in near term
12.31.24
$CVKD $14.65 +0.42. *DAC (dollar average cost adjusted for 1:15 split) $10.39.
BRIEF: Cadrenal Therapeutics Looks Ahead To 2025 And Initiation Of Pivotal Phase 3 Clinical Trial For Tecarfarin In Left Ventricular Assist Devices.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
12.31.24
$VSTM $4.82 +1.17. DAC (dollar average cost) $2.85 (9.30.24). EXIT $10.00.
RETAIN SPM TAG EXIT.
BRIEF: BTIG Research raises their VSTM tgt to $20 from $13. Analyst Justin Zelin noted, "... VSTM announced that FDA has accepted the company's NDA filing for Avutometinib in combination with Defactinib for the treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (LGSOC) under priority review with a PDUFA date set for June 30th, 2025. We expect FDA approval for the combination by mid-2025 marking the first FDA approved treatment option for women with KRASm LGSOC. With FDA acceptance of the NDA under priority review, and our increased confidence following our recent KOL call, we have increased our modeled probability of success in KRASm from 65% to 80% which correspondingly increases our PT from $13 to $20, and we reiterate our Buy rating. "
12.31.24
$VSTM $4.65 +1.03. DAC (dollar average cost) $2.85 (9.30.24). EXIT $10.00.
UPDATE: FDA Acceptance and Priority Review of New Drug Application for Avutometinib.
12.31.24
$POET $6.38 bid. DAC (dollar average cost) $3.35 (9.23.24). EXIT $10.00.
BRIEF: Completed its previously-announced acquisition of control of Super Photonics Integrated Circuit Xiamen Co., Ltd. (company jointly held by, and previously operated as a joint venture between, the Company and Quanzhou San'an Optical Communication Technology Co., Ltd. ("SAIC" or "Sanan").
12.31.24
$ACAD $18.01 bid. *DAC (dollar average cost includes partial liquidate to reduce cost to $13.02).
EXIT $23.00.
BRIEF: S&P SmallCap 600 inclusion.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
12.30.24
$MVIS $1.60 +0.09. DAC (dollar average cost) (4) $0.91 / last $$0.895 (12.18.24. EXIT $3.00.
OVERVIEW: On RSI score.
On 12.19.24 , WestPark Capital analyst Casey Ryan initiated coverage on Microvision(MVIS) with a Buy rating and announced a price targe t of $1.3. The company's stock gained around 56% over the past five days and has a 52-week high of $2.87.
RSI Value: 70
MVIS Price Action: Shares of Microvision ($MVIS) gained 8.6% to close at $1.51 on Friday.
note: The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to SPM tag.
12.30.24
$AMLX $4.07 bid. DAC (dollar average cost) $1.86 (8.12.24). EXIT $10.00.
UPDATE: At the end of the screening period, the Company and Gubra anticipate identifying a lead development candidate to enter Investigational New Drug ("IND")-enabling studies. The Company then has the option to lead development once the long-acting GLP-1 receptor antagonist has been identified. Under the agreement, the Company will make a small upfront payment and research payments to Gubra, and Gubra is eligible to receive more than $50 million in success-based development and commercialization milestones plus mid-single digit royalties on worldwide net sales.
note: The upfront and research payments are not material for the Company; continues to expect cash runway into 2026.
12.30.24
$LPSN $1.09 ask. BUY/ADD TO LONG POSITION. DAC (dollar average cost) (2) $1.155. EXIT $2.25 in near term.
PART TWO:
On January 2, 2025 we began Beta testing eight new data fields as a means to anticipate and react to the evolving dynamics of political realities and related trading anomalies. The intention is to enhanced the subsets from 129 to 137 by operating two separate systems until the new data stream is fully integrated. Any modification, if necessary, to the generative subsets will be introduced to the platform and become effective March 1, 2025. Once complete and fully operational, we plan to commence a new service called G-101 SPM AI Email Platform Component – EPC for all FLASHTRADES, short term and midterm term trading ideas, and immediately transmit the data to private email addresses of our subscribers, and repost the data the following day to our Stocktwists landing pages.
________________________
MISSION STATEMENT: To prove that non-human intervention by an analytical dotbot is far superior than the other kinds. The rise of generative AI (GenAI) models, like OpenAI’s GPT, has accelerated our transformation. In the process we have become Number One in non-human investment/enterprise analytics.
Our tools do more than process data, G-101 SPM AI generates world-class content, fully automated workflows, and unlocks insights in ways traditional AI can never achieve.

HOW MUCH MONEY DID YOU MAKE THIS WEEK?
Commentaires